Literature DB >> 19924781

Large intragenic deletions of the NF2 gene: breakpoints and associated phenotypes.

Benjamin Abo-Dalo1, Kerstin Kutsche, Victor Mautner, Lan Kluwe.   

Abstract

In this study, the breakpoints of six large intragenic deletions in the NF2 gene are determined, which had initially been detected by multiplex ligation-dependent probe amplification. While one breakpoint occurred within an exon, the remaining 11 lied in the corresponding flanking introns. Two of the deletions were most likely caused by nonallelic homologous recombination between Alu sequences, while the other four appeared to be the result of nonhomologous endjoining, possibly facilitated by rearrangement-promoting elements at the junctions in some cases. The clinical features of patients with large intragenic deletions and individuals with mutations affecting single or multiple nucleotides of the NF2 gene are relatively similar. However, patients with deletions of the 3' exons 15 and 16 of the NF2 gene did exhibit milder phenotypes, especially with respect to the age of disease onset.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19924781     DOI: 10.1002/gcc.20733

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

Review 1.  On the sequence-directed nature of human gene mutation: the role of genomic architecture and the local DNA sequence environment in mediating gene mutations underlying human inherited disease.

Authors:  David N Cooper; Albino Bacolla; Claude Férec; Karen M Vasquez; Hildegard Kehrer-Sawatzki; Jian-Min Chen
Journal:  Hum Mutat       Date:  2011-09-02       Impact factor: 4.878

2.  Alternative outcomes of pathogenic complex somatic structural variations in the genomes of NF1 and NF2 patients.

Authors:  Meng-Chang Hsiao; Arkadiusz Piotrowski; Andrzej Brunon Poplawski; Tom Callens; Chuanhua Fu; Ludwine Messiaen
Journal:  Neurogenetics       Date:  2017-03-11       Impact factor: 2.660

3.  BTECH: a platform to integrate genomic, transcriptomic and epigenomic alterations in brain tumors.

Authors:  Min Wang; Hehuang Xie; Wendy Stellpflug; Veena Rajaram; Maria de Fatima Bonaldo; Stewart Goldman; Tadanori Tomita; Marcelo Bento Soares
Journal:  Neuroinformatics       Date:  2011-03

4.  The molecular biology of vestibular schwannomas and its association with hearing loss: a review.

Authors:  Erika Celis-Aguilar; Luis Lassaletta; Miguel Torres-Martín; F Yuri Rodrigues; Manuel Nistal; Javier S Castresana; Javier Gavilan; Juan A Rey
Journal:  Genet Res Int       Date:  2012-02-20

5.  Genetic Severity Score predicts clinical phenotype in NF2.

Authors:  Dorothy Halliday; Beatrice Emmanouil; Pieter Pretorius; Samuel MacKeith; Sally Painter; Helen Tomkins; D Gareth Evans; Allyson Parry
Journal:  J Med Genet       Date:  2017-08-28       Impact factor: 6.318

6.  Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients.

Authors:  Isabel Gugel; Lan Kluwe; Julian Zipfel; Christian Teuber; Marcos Tatagiba; Victor-Felix Mautner; Martin Ulrich Schuhmann; Florian Grimm
Journal:  Cancers (Basel)       Date:  2019-11-25       Impact factor: 6.639

Review 7.  Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.

Authors:  Christine T Dinh; Eric Nisenbaum; Darius Chyou; Carly Misztal; Denise Yan; Rahul Mittal; Juan Young; Mustafa Tekin; Fred Telischi; Cristina Fernandez-Valle; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2020-06       Impact factor: 2.619

8.  Cerebrovascular Insult as Presenting Symptom of Neurofibromatosis Type 2 in Children, Adolescents, and Young Adults.

Authors:  Isabel Gugel; Victor-Felix Mautner; Lan Kluwe; Marcos Soares Tatagiba; Martin Ulrich Schuhmann
Journal:  Front Neurol       Date:  2018-09-10       Impact factor: 4.003

9.  Impact of Surgery on Long-Term Results of Hearing in Neurofibromatosis Type-2 Associated Vestibular Schwannomas.

Authors:  Isabel Gugel; Florian Grimm; Marina Liebsch; Julian Zipfel; Christian Teuber; Lan Kluwe; Victor-Felix Mautner; Marcos Tatagiba; Martin Ulrich Schuhmann
Journal:  Cancers (Basel)       Date:  2019-09-16       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.